Home/Recalls/FDA-Z-1638-2026
FDA DevicesClass II

Brand Name: Olympus Everest Bipolar Cutting Forceps, 5 mm 33 cm Product Name: E...

Published: April 1, 2026Recall ID: Z-1638-2026Category: devicesCountry: US

Reason for Recall / Hazard

Olympus identified that the Cutting Forceps contain components for which the supplier did not adequately validate the welding process. Defective welds can result in the Cutting Forceps' jaw breaking during clinical use.

Product Description & Identification

Brand Name: Olympus Everest Bipolar Cutting Forceps, 5 mm 33 cm Product Name: Everest Bipolar Cutting Forceps Model/Catalog Number: 3005 Product Description: The OLYMPUS Everest Bipolar Cutting Forceps are intended to be passed through a 5 mm cannula. Coagulation is achieved using electrosurgical energy under visualization. The device is intended to be used with the bipolar outputs of compatible generators.

Affected Products

Brand Name: Olympus Everest Bipolar Cutting Forceps, 5 mm 33 cm Product Name: Everest Bipolar Cutting Forceps Model/Catalog Number: 3005 Product Description: The OLYMPUS Everest Bipolar Cutting Forceps are intended to be passed through a 5 mm cannula. Coagulation is achieved using electrosurgical energy under visualization. The device is intended to be used with the bipolar outputs of compatible generators.

Additional Source Details

FieldValue
CityCenter Valley
StatePA
Event id98454
Address 13500 Corporate Pkwy
Code infoModel: 3005; UDI: 00821925035881; Lot Number: All unexpired
Postal code18034-8229
Report date20260401
Product typeDevices
Product quantity106 units
Reason for recallOlympus identified that the Cutting Forceps contain components for which the supplier did not adequately validate the welding process. Defective welds can result in the Cutting Forceps' jaw breaking during clinical use.
Voluntary mandatedVoluntary: Firm initiated
Recall initiation date20260225
Initial firm notificationLetter
Center classification date20260325

Overview

  • Recalling FirmOlympus Corporation of the Americas
  • StatusOngoing
  • Risk LevelClass II
  • DistributionWorldwide - US Nationwide and the countries of Canada, Mexico, EU, Australia, China, Singapore, Korea, Japan.
Official Agency Alert